1. Home
  2. ARVN vs EHAB Comparison

ARVN vs EHAB Comparison

Compare ARVN & EHAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.96

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Logo Enhabit Inc.

EHAB

Enhabit Inc.

HOLD

Current Price

$13.80

Market Cap

706.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
EHAB
Founded
2015
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Hospital/Nursing Management
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
658.2M
706.9M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
ARVN
EHAB
Price
$8.96
$13.80
Analyst Decision
Buy
Hold
Analyst Count
19
5
Target Price
$15.05
$13.84
AVG Volume (30 Days)
854.3K
1.1M
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
58.84
97.11
EPS
N/A
0.36
Revenue
$262,600,000.00
$1,060,000,000.00
Revenue This Year
N/A
$5.57
Revenue Next Year
N/A
$4.20
P/E Ratio
N/A
$38.33
Revenue Growth
N/A
2.44
52 Week Low
$6.06
$6.47
52 Week High
$14.22
$14.22

Technical Indicators

Market Signals
Indicator
ARVN
EHAB
Relative Strength Index (RSI) 35.45 61.96
Support Level $7.35 $10.79
Resistance Level $10.18 $14.22
Average True Range (ATR) 0.51 0.02
MACD -0.03 -0.01
Stochastic Oscillator 23.34 87.50

Price Performance

Historical Comparison
ARVN
EHAB

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About EHAB Enhabit Inc.

Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.

Share on Social Networks: